Filing Flows › Health Care › Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG (CRSP) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Crispr Therapeutics AG (CRSP) Q3 2026 earnings results →
Q3 2026 Revenue up 1325% year over year to $12.7M · 880¢ of every $1 of revenue lost
Crispr Therapeutics AG made $12.7M in Q3 2026 (14× Y/Y): Collaboration Revenue $12.3M, Grant $346K. Operating margin n/m, net loss $111M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12.7M in Q3 2026, up 1325% year over year and up 24% from the previous quarter. Collaboration Revenue was the largest line at 97% of revenue. Grant declined 61%.
Operating costs exceeded revenue by $130.0M, an operating margin of -1026.5%. Total costs grew 7% against revenue growth of 1325%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $111.4M, wider than the previous quarter's $91.2M loss.
Operating cash flow was −$89.7M. Non-cash charges added back $4.2M of depreciation and amortization and $18.0M of share-based compensation. Capital expenditures of $414K exceeded it, leaving free cash flow of −$90.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $12.7M | 14× | n/m | −$111M | −$89.7M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $10.2M | 11× | n/m | −$91.2M | −$83.5M |
| Q1 2026 | 10-Q | May 4, 2026 | $1.5M | +69% | n/m | −$123M | −$109M |
| Q4 2025 | 10-K | Feb 12, 2026 | $864K | -98% | n/m | −$131M | −$92.6M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $889K | +48% | n/m | −$106M | −$84.6M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $892K | +72% | n/m | −$209M | −$114M |
| Q1 2025 | 10-Q | May 6, 2025 | $865K | +72% | n/m | −$136M | −$53.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Crispr Therapeutics AG
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
In its own words, from its 10-K, filed Feb 12, 2026.
Crispr Therapeutics AG against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 14× against the peers' median +29%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CRSP Crispr Therapeutics AG | Q3 2026 | $12.7M | 14× | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Crispr Therapeutics AG 10-Q on SEC EDGAR · CIK 1674416 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
More on CRSP
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results